LFMD
LifeMD, Inc.
NASDAQ · Healthcare · Medical - Pharmaceuticals · US
$3.08
+0.98%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 204.5M | 194.1M | 212.5M | 152.5M | 119.0M |
| Cost of Revenue | 28.8M | 39.3M | 24.1M | 18.9M | 18.7M |
| Gross Profit | 175.7M | 154.8M | 188.4M | 133.6M | 100.4M |
| Operating Expenses | |||||
| R&D Expense | 4.8M | 7.3M | 9.5M | 6.1M | 3.0M |
| SG&A Expense | 167.4M | 144.0M | 175.7M | 128.1M | 125.3M |
| General & Admin Expense | 45.4M | 57.9M | 72.7M | 51.7M | 47.0M |
| Selling & Marketing Expense | 87.4M | 86.1M | 103.0M | 76.5M | 78.4M |
| Other Expenses | 22.6M | 11.1M | 19.3M | 13.9M | 15.5M |
| Total Operating Expenses | 194.8M | 162.4M | 204.5M | 148.1M | 143.8M |
| Cost and Expenses | 223.6M | 201.7M | 228.6M | 167.0M | 162.5M |
| Operating Income (EBIT) | (19.1M) | (7.7M) | (16.1M) | (14.5M) | (43.4M) |
| Non-Operating | |||||
| Interest Income | 126.2K | — | — | — | — |
| Interest Expense | 262.5K | 1.4M | 2.2M | 2.6M | 1.3M |
| Net Interest Income | (136.2K) | (1.4M) | (2.2M) | (2.6M) | (1.3M) |
| Other Non-Op Income/Expense | (1.3M) | (2.5M) | (2.2M) | (2.9M) | (1.2M) |
| Non-Operating Income (excl Interest) | 1.0M | 1.2M | (183.00) | 325.2K | (3.8M) |
| EBT (Pre-Tax Income) | (20.4M) | (10.2M) | (18.3M) | (17.4M) | (44.7M) |
| Income Tax Expense | 183.0K | 45.7K | 402.0K | 428.0K | 360.7K |
| Bottom Line | |||||
| Net Income | (21.3M) | (7.1M) | (18.9M) | (20.6M) | (45.5M) |
| Earnings from Cont. Ops | (20.6M) | (10.2M) | (18.7M) | (17.8M) | (45.0M) |
| Earnings from Discont. Ops | (409.3K) | 3.1M | — | — | — |
| Bottom Line Net Income | (24.4M) | (10.2M) | (22.0M) | (23.7M) | (48.6M) |
| Per Share | |||||
| Basic EPS | ($0.51) | ($0.23) | ($0.53) | ($0.70) | ($1.57) |
| Diluted EPS | ($0.51) | ($0.23) | ($0.53) | ($0.70) | ($1.57) |
| Revenue Per Share | $4.28 | $4.30 | $5.16 | $4.50 | $3.84 |
| Shares | |||||
| Basic Shares Outstanding | 47.8M | 45.1M | 41.2M | 33.9M | 31.0M |
| Diluted Shares Outstanding | 47.8M | 45.1M | 41.2M | 33.9M | 31.0M |
| Profitability Metrics | |||||
| EBITDA | (13.2M) | (1.5M) | (6.7M) | (8.2M) | (38.6M) |
| D&A | 6.9M | 7.3M | 9.5M | 6.6M | 1.1M |
| EBIT | (20.2M) | (8.8M) | (16.1M) | (14.8M) | (39.7M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026